Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYH2059, a highly selective PDE4B inhibitor delivered as an inhaled powder, with prior clearance already granted by the U.S. FDA. The novel drug, aimed at treating interstitial lung disease where current options are limited, has shown superior efficacy and safety in preclinical studies and marks a key milestone for CSPC’s high-end inhalation technology platform, strengthening its innovative pipeline and positioning in respiratory therapeutics.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing innovative drugs, including chemical and biologic therapies. The group has been building high-end technology platforms such as inhalation formulations to target unmet medical needs in respiratory and other serious diseases in China and global markets.
YTD Price Performance: 1.90%
Average Trading Volume: 121,065,610
Technical Sentiment Signal: Buy
Current Market Cap: HK$98.81B
See more data about 1093 stock on TipRanks’ Stock Analysis page.